ERα和AROM在上皮性卵巢癌中的表达及临床意义
|
摘要
目的:探讨上皮性浆液性卵巢癌、卵巢良性肿瘤及正常卵巢组织中雌激素受体α(ERα)与芳香化酶(AROM)的表达。方法:采用免疫组化检测ERα与AROM在卵巢上皮性浆液性癌、卵巢良性肿瘤及正常卵巢组织中表达情况,并结合临床资料进行统计分析。结果:卵巢癌组织中ERα高表达、AROM低表达,与正常卵巢组织及良性肿瘤组织中表达情况比较,差异均有统计学意义(P<0.05)。结论:上皮性浆液性卵巢癌中ERα高表达及AROM低表达,提示ERα选择性抑制剂可能是防治卵巢癌发生的可行途径之一,而AROM低表达与ERα高表达之间可能存在相关因子表达通路,为卵巢癌治疗提供了新思路。
Objective:To study the expressions of ERα and AROM in epithelial serous ovarian cancer,benign ovarian tumor and normal ovarian tissue.Method:The expression of ERα and AROM in ovarian epithelial serous carcinoma,benign ovarian tumor and normal ovarian tissue were detected by immunohistochemistry technique.Summarized the relevant clinical data for analysis.Result:The high expression of ERα and the low expression of AROM in ovarian cancer tissues were significantly different from those in normal ovarian tissues and benign tumor tissues(P<0.05).Conclusion:High expression of ERα and low expression of AROM in epithelial serous ovarian cancer are associated,suggesting that ERα selective inhibitor may be one of the feasible ways to prevent ovarian cancer.However,there may be a related factor expression pathway between the low expression of AROM and the high expression of ERα,which provides new ideas and methods for the treatment of ovarian cancer.
Objective:To study the expressions of ERα and AROM in epithelial serous ovarian cancer,benign ovarian tumor and normal ovarian tissue.Method:The expression of ERα and AROM in ovarian epithelial serous carcinoma,benign ovarian tumor and normal ovarian tissue were detected by immunohistochemistry technique.Summarized the relevant clinical data for analysis.Result:The high expression of ERα and the low expression of AROM in ovarian cancer tissues were significantly different from those in normal ovarian tissues and benign tumor tissues(P<0.05).Conclusion:High expression of ERα and low expression of AROM in epithelial serous ovarian cancer are associated,suggesting that ERα selective inhibitor may be one of the feasible ways to prevent ovarian cancer.However,there may be a related factor expression pathway between the low expression of AROM and the high expression of ERα,which provides new ideas and methods for the treatment of ovarian cancer.
引文
[1]韩丽萍,董子明,乔玉环,等.卵巢上皮性癌组织中雌激素受体亚型的表达[J].四川大学学报:医学版,2006(4):606-610.
[2]刘梦娜,谢静燕,赵树立.雌激素受体在卵巢癌研究中的进展[J].东南大学学报:医学版,2014,33(2):215-218.
[3]卢义函,王应海,李春琳,等.激素替代治疗与妇科恶性肿瘤的研究进展[J].昆明理工大学学报:自然科学版,2016,41(6):86-91.
[4]陈飞,何成章,吴玉玉.上皮性卵巢肿瘤中雌激素受体亚型表达的研究[J].徐州医学院学报,2004(2):124-126.
[5]Ikeda K,Inoue S.Estrogen receptors and their downstream targets in cancer[J].Arch Histol Cytol,2004,67(5):435-442.
[6]Vadlamudi R K,Rajhans R,Chakravarty D,et al.Regulation of aromatase induction by nuclear receptor coregulator PELP1[J].J Steroid Biochem Mol Biol,2010,118(4-5):211-218.
[7]马晓欣,张淑兰,高山,等.芳香化酶蛋白及性激素受体等在子宫内膜病变组织中的表达变化及意义[J].中华妇产科志,2006,41(6):395-398.
[8]石秀杰.子宫内膜异位症与芳香化酶P450、雌激素受体及其亚型的研究进展[J].中国医药指南,2012,10(9):389-390.
[9]马爱清,张秦,刘琦.芳香化酶P450Arom在卵巢浆液性腺癌的表达及临床意义[J].肿瘤学杂志,2014,20(1):6-10.
[10]冯婷,柴芸,周坚红.P450Arom,雌激素受体α在浆液性卵巢癌中的表达[J].肿瘤学杂志,2010,16(7):569-571.
[11]韩丽丽,王华杰,张慧慧,等.卵巢上皮性癌雌激素受体、孕激素受体的表达及与其预后的关系[J].中国实验诊断学,2016,20(7):1106-1108.
[12]李婉,孙丽美,刘禹池,等.激素受体与卵巢癌预后、发病机制及治疗的研究进展[J].现代肿瘤医学,2017,25(4):657-660.
[2]刘梦娜,谢静燕,赵树立.雌激素受体在卵巢癌研究中的进展[J].东南大学学报:医学版,2014,33(2):215-218.
[3]卢义函,王应海,李春琳,等.激素替代治疗与妇科恶性肿瘤的研究进展[J].昆明理工大学学报:自然科学版,2016,41(6):86-91.
[4]陈飞,何成章,吴玉玉.上皮性卵巢肿瘤中雌激素受体亚型表达的研究[J].徐州医学院学报,2004(2):124-126.
[5]Ikeda K,Inoue S.Estrogen receptors and their downstream targets in cancer[J].Arch Histol Cytol,2004,67(5):435-442.
[6]Vadlamudi R K,Rajhans R,Chakravarty D,et al.Regulation of aromatase induction by nuclear receptor coregulator PELP1[J].J Steroid Biochem Mol Biol,2010,118(4-5):211-218.
[7]马晓欣,张淑兰,高山,等.芳香化酶蛋白及性激素受体等在子宫内膜病变组织中的表达变化及意义[J].中华妇产科志,2006,41(6):395-398.
[8]石秀杰.子宫内膜异位症与芳香化酶P450、雌激素受体及其亚型的研究进展[J].中国医药指南,2012,10(9):389-390.
[9]马爱清,张秦,刘琦.芳香化酶P450Arom在卵巢浆液性腺癌的表达及临床意义[J].肿瘤学杂志,2014,20(1):6-10.
[10]冯婷,柴芸,周坚红.P450Arom,雌激素受体α在浆液性卵巢癌中的表达[J].肿瘤学杂志,2010,16(7):569-571.
[11]韩丽丽,王华杰,张慧慧,等.卵巢上皮性癌雌激素受体、孕激素受体的表达及与其预后的关系[J].中国实验诊断学,2016,20(7):1106-1108.
[12]李婉,孙丽美,刘禹池,等.激素受体与卵巢癌预后、发病机制及治疗的研究进展[J].现代肿瘤医学,2017,25(4):657-660.